The early GO decision and Orphan Drug Designation materially de-risk claseprubart's clinical and regulatory path. Monitor for CAPTIVATE Part B top-line guidance by YE 2026 and Phase 3 gMG trial initiation in mid-2026 as the next major catalysts.
Price Chart
Executive Summary
Dianthus Therapeutics reported Q1 2026 net loss of $40.8M ($0.85/share) and highlighted major pipeline progress: early GO decision in Phase 3 CAPTIVATE CIDP trial, FDA Orphan Drug Designation for claseprubart in myasthenia gravis, and selection of three initial indications for DNTH212. Cash of $1.2B provides runway into 2030, removing near-term financing risk.
Key Financial Metrics
Key Facts
- Early GO decision reached in Phase 3 CAPTIVATE CIDP trial after 20 confirmed responders with <40 patients completing Part A.
- Claseprubart granted FDA Orphan Drug Designation for myasthenia gravis.
- Cash, cash equivalents and investments of $1.2B as of March 31, 2026, providing runway into 2030.
- Closed upsized public offering with gross proceeds of ~$719 million on March 12, 2026.
- Net loss for Q1 2026: $40.8M ($0.85/share) vs. $29.5M ($0.82/share) in Q1 2025.
- Phase 2 MoMeNtum MMN trial top-line results on track for Q4 2026; Phase 3 EMERGE gMG trial to initiate mid-2026 with 2H 2028 top-line.
- First three priority indications for DNTH212: Sjögren's Disease, SLE, Dermatomyositis.
Financial Impact
Q1 2026 net loss of $40.8M ($0.85/share) vs $29.5M ($0.82/share) in prior year; revenue of $463K (license) vs $1.163M. No financial guidance provided.
Risk Factors
- Clinical trial failure in upcoming Phase 3 or Phase 2 readouts.
- Competition from approved complement inhibitors and other therapies.
- Dilution from the March 2026 offering; ~48M shares outstanding post-offering.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001690585-26-000021 |
| Document: dnth-20260505.htm | 0001690585-26-000021 |
| Document: 0001690585-26-000021-index-headers.html | 0001690585-26-000021 |
| Document: 0001690585-26-000021-index.html | 0001690585-26-000021 |
| Document: 0001690585-26-000021.txt | 0001690585-26-000021 |
| 8-K Data (Synthetic) | 0001690585-26-000021 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 7w ago | Insider Cluster | $112.41 $103.28 | ▼ −8.12% | ▼ −6.22% | $89.96 (−19.97%) |
Aug 11, 2026 7w ago | Insider Cluster | $112.41 $103.28 | ▼ −8.12% | ▼ −6.22% | $89.96 (−19.97%) |
Aug 11, 2026 7w ago | Insider Cluster | $112.41 $103.28 | ▼ −8.12% | ▼ −6.22% | $89.96 (−19.97%) |
Aug 11, 2026 7w ago | Insider Cluster | $112.41 $103.28 | ▲ +8.12% | ▲ +6.22% | $89.96 (+19.97%) |
Aug 10, 2026 7w ago | 144 | $108.49 $107.04 | ▼ −1.34% | ▼ −0.28% | $89.96 (−17.08%) |
Jun 29, 2026 13w ago | Press Release | $95.68 $103.87 | ▲ +8.56% | ▲ +8.84% | $89.96 (−5.98%) |
Jun 12, 2026 16w ago | 8-K | $82.07 $97.60 | ▲ +18.92% | ▲ +17.14% | $89.96 (+9.61%) |
Jun 11, 2026 16w ago | Institutional Cluster | $76.45 $100.03 | ▲ +30.84% | ▲ +28.95% | $89.96 (+17.67%) |
May 5, 2026 21w ago | 8-K | $90.42 $84.97 | ▼ −6.03% | ▼ −8.81% | $89.96 (−0.51%) |
Mar 12, 2026 29w ago | Press Release | $77.86 $90.00 | ▲ +15.59% | ▲ +12.00% | $89.96 (+15.54%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access